Sequence information
Variant position: 154 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: 443 The length of the canonical sequence.
Location on the sequence:
TAVAMPMLYNTRYSSKRRVT
V MISIVWVLSFTISCPLLFGL
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human TAVAMPMLYNTRYSSKRRVTV MISIVWVLSFTISCPLLFGL
TAVAMPMLYNTRYSSKRRVTV MIAIVWVLSFTISCPLLFGL
Chimpanzee TAVAMPMLYNTRYSSKRRVTV MISIVWVLSFTISCPLLFGL
Mouse TAVAMPMLYNTRYSSKRRVTV MIAIVWVLSFTISCPLLFGL
Rat TAVAMPMLYNTRYSSKRRVTV MIAIVWVLSFTISCPLLFGL
Bovine TAVAMPMLYNTRYSSKRRVTV MIAIVWVLSFTISCPMLFGL
Sequence annotation in neighborhood: The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:Type: the type of sequence feature. Positions: endpoints of the sequence feature. Description: contains additional information about the feature.
Literature citations
Association of a missense change in the D2 dopamine receptor with myoclonus dystonia.
Klein C.; Brin M.F.; Kramer P.; Sena-Esteves M.; de Leon D.; Doheny D.; Bressman S.; Fahn S.; Breakefield X.O.; Ozelius L.J.;
Proc. Natl. Acad. Sci. U.S.A. 96:5173-5176(1999)
Cited for: VARIANT ILE-154;
Evaluation of the role of the D2 dopamine receptor in myoclonus dystonia.
Klein C.; Gurvich N.; Sena-Esteves M.; Bressman S.; Brin M.F.; Ebersole B.J.; Fink S.; Forsgren L.; Friedman J.; Grimes D.; Holmgren G.; Kyllerman M.; Lang A.E.; de Leon D.; Leung J.; Prioleau C.; Raymond D.; Sanner G.; Saunders-Pullman R.; Vieregge P.; Wahlstrom J.; Breakefield X.O.; Kramer P.L.; Ozelius L.J.; Sealfon S.C.;
Ann. Neurol. 47:369-373(2000)
Cited for: CHARACTERIZATION OF VARIANT ILE-154;
Disclaimer:
Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.